Date: 2018-05-08
Type of information: Nomination
Compound: president and chief executive officer
Company: Audentes Therapeutics (USA - CA)
Therapeutic area: Rare diseases - Genetic diseases
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On May 8, 2018, Audentes Therapeutics announced the promotion of Natalie Holles from Senior Vice President and Chief Operating Officer to President and Chief Operating Officer. In this new role, Ms. Holles will oversee the day-to-day operations of the company, including research, development, manufacturing, program management and corporate development.
- Ms. Holles joined Audentes in 2015, bringing 15 years of corporate development, strategic planning, and commercial experience gained in a range of therapeutic areas and with a focus on rare diseases. Prior to joining Audentes, Ms. Holles served as Senior Vice President, Corporate Development at Hyperion Therapeutics from 2013 through its acquisition by Horizon Pharma, plc in May 2015. From 2010 to 2013, Ms. Holles provided executive-level strategy and business development advisory services to a number of privately-held biopharmaceutical companies. Earlier in her career, Ms. Holles served as Vice President, Business Development at KAI Pharmaceuticals (acquired by Amgen in 2012) and previously held corporate development and commercial roles at InterMune (acquired by Roche in 2014) and Genentech. Ms. Holles holds an M.A. in molecular, cellular and developmental biology from the University of Colorado, Boulder, where she was a Howard Hughes Medical Institute Predoctoral Fellow, and an A.B. in Human Biology from Stanford University.
Financial terms:
Latest news:
Is general: Yes
